The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival
Anna Martner
• 25 Feb 2019
Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses the mechanism of action of the combination of histamine dihydrochloride and IL-2, and its impacts for relapse risk and survival in acute myeloid leukemia (AML). This interview was held at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
